Events & Ideas

June 19-23, 2023 | Denver, CO Judy Ashworth will be attending. VIEW CONFERENCE

Moline ML, Cheng JY, Durgin C, Pype S, Buchhalter A, Henningfield J To identify differences and similarities in real-world abuse potential between dual orexin receptor antagonists (DORAs) and other drugs used as hypnotics, either Schedule IV (CIV) or unscheduled. DORAs, the newest hypnotic class, were placed in CIV based largely on human abuse potential (HAP)… Read More

June 17-21, 2023 | Denver, CO Judy Ashworth, Jack Henningfield, August Buchhalter, Ryan Lanier and Caitlyn Durgin will be attending. VIEW CONFERENCE WEBSITE Posters: A Novel 3 mg Naloxone Nasal Spray for the Over-the-Counter Market Abuse Potential Similarities Between Hypnotic Classes: Real-World Data Differing Approaches to Investigating the Therapeutic Efficacy of Psilocybin across Diverse Indications

Lanier R, Schindler E, Kelmendi B, Bogenschutz M, Durgin C, Ashworth J Psilocybin and other psychedelics are currently being investigated for their potential to treat or assist in the treatment of a range of neurological and psychiatric conditions, including substance use disorders. These conditions have overlapping, but distinct pathophysiologies and treatment modalities. How, then, is… Read More

Moline ML, Cheng JY, Durgin C, Pype S, Buchhalter A, Henningfield J The two major hypnotic classes with distinct mechanisms of action, GABAergic drugs (benzodiazepines [BZs] and nonbenzodiazepines [i.e. zolpidem]) and dual orexin receptor antagonists (DORAs), are Schedule IV (CIV) drugs, but have notable differences in human abuse profiles. BZs are associated with drug tolerance/dependence,… Read More

Belouin SJ, Averill LA, Henningfield JE, Xenakis SN, Donato I, Grob CS, Berger A, Magar V, Danforth AL, Anderson BT. Neuropharmacology. 2022 Nov 15;219:109214. View publication

Ross S, Agrawal M, Griffiths RR, Grob C, Berger A, Henningfield JE. Neuropharmacology. 2022 Sep 15;216:109174. View publication

Henningfield JE, Ashworth J, Heal DJ, Smith SL. J Psychopharmacol. 2023 Jan 1:2698811221140004. View publication